Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21294.
   PubMed Web of Science ®Google Scholar
• Smolewski P, Witkowska M, Robak T. Treatment options for mantle cell lymphoma. Expert Opin Pharmacother. 2015;16:2497–2507. doi:10.1517/14656566.2015.1087507.
   PubMed Web of Science ®Google Scholar
• Lenz G, Staudt ML. Aggressive lymphomas. N Engl J Med. 2010;362:1417–1429. doi:10.1056/NEJMra0807082.
   PubMed Web of Science ®Google Scholar
• Mani A, Gelmann EP. The ubiquitin–proteasome pathway and its role in cancer. J Clin Oncol. 2005;23:4776–4789. doi:10.1200/JCO.2005.05.081.
   PubMed Web of Science ®Google Scholar
• Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–381. doi:10.1038/nrc1881.
   PubMed Web of Science ®Google Scholar
• Chen L, Juszczynski P, Takeyama K, et al. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006;108:3428–3433. doi:10.1182/blood-2006-03-013821.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Bartlett NL, Blum KA, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016;54:11–17. doi:10.1016/j.ejca.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–551. doi:10.1056/NEJMoa1306220.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–926. DOI:10.1038/nm.3884
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372:1430–1440. doi:10.1056/NEJMoa1501548.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Christian B, Jaglowski S, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125:242–248. doi:10.1182/blood-2014-08-597914.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203. doi:10.1182/blood-2016-03-707133.
   PubMed Web of Science ®Google Scholar
• Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5:1602–1609.
   PubMed Web of Science ®Google Scholar
• Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol. 2014;167:19–32. doi:10.1111/bjh.13065.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–3405. DOI:10.1182/blood-2013-11-537555
   PubMed Web of Science ®Google Scholar
• Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep. 2009;11:102–110.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053–4062. doi:10.1182/blood-2005-08-3434.
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumour efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:2276–2286. doi:10.1158/1535-7163.MCT-10-0338.
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des. 2012;18:2766–2777.
   PubMed Web of Science ®Google Scholar
• Smith SM. Clinical development of mTOR inhibitors: a focus on lymphoma. Rev Recent Clin Trials. 2007;2:103–110.
   PubMedGoogle Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829. DOI:10.1200/JCO.2008.20.7977
   PubMed Web of Science ®Google Scholar
• Hess G, Keller U, Scholz CW, et al. Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. 2015;29:1695–1701. doi:10.1038/leu.2015.60.
   PubMed Web of Science ®Google Scholar
• Inwards DJ, Fishkin PA, LaPlant BR, et al. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol. 2014;25:2020–2024. doi:10.1093/annonc/mdu273.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Jacobsen E, Feng Y, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013;98:615–619. DOI:10.3324/haematol.2012.075184
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–684. doi:10.1200/JCO.2005.02.050.
   PubMed Web of Science ®Google Scholar
• Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29:3389–3395. doi:10.1200/JCO.2010.32.1844.
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383–6391. doi:10.1158/0008-5472.CAN-06-4086.
   PubMed Web of Science ®Google Scholar
• Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2000;18:1812–1823.
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–3428. doi:10.1158/0008-5472.CAN-07-5836.
   PubMed Web of Science ®Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149–1159. DOI:10.1016/S1470-2045(10)70261-8
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784. doi:10.1038/nrd2133.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:1198–1203. DOI:10.1200/JCO.2010.32.1398
   PubMed Web of Science ®Google Scholar
• Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10:387–402. doi:10.1038/nri2765.
   PubMed Web of Science ®Google Scholar
• Turner M, Schweighoffer E, Colucci F, et al. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000;21:148–154.
   PubMedGoogle Scholar
• Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230–2237. doi:10.1182/blood-2007-07-100115.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:3827–3834. doi:10.1182/blood-2009-12-255992.
   PubMed Web of Science ®Google Scholar
• Lamb DJ, Wollin SL, Schnapp A, et al. BI 1002494, a novel potent and selective oral spleen tyrosine kinase inhibitor, displays differential potency in human basophils and B cells. J Pharmacol Exp Ther. 2016;357:554–561. doi:10.1124/jpet.116.233155.
   PubMed Web of Science ®Google Scholar
• Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;125:2336–2343. doi:10.1182/blood-2014-08-595934.
   PubMed Web of Science ®Google Scholar
• Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules. 2014;19:14304–14315. doi:10.3390/molecules190914304.
   PubMed Web of Science ®Google Scholar
• Vega GG, Avilés-Salas A, Chalapud JR, et al. P38 MAPK expression and activation predicts failure of response to CHOP in patients with diffuse large B-cell lymphoma. BMC Cancer. 2015 Oct 16;15:722. DOI:10.1186/s12885-015-1584-3.
   PubMed Web of Science ®Google Scholar
• Badar T, Cortes JE, Ravandi F, et al. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015;15:433–438.e2. doi:10.1016/j.clml.2015.02.018.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134. doi:10.1056/NEJMc063190.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835–844. doi:10.1038/nrd2130.
   PubMed Web of Science ®Google Scholar
• Greenwald DR, Li H, Luger SM, et al. A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an Eastern Cooperative Oncology Group study (E1404). J Hematol Oncol. 2013;6(1):46. DOI:10.1186/1756-8722-6-46.
   PubMed Web of Science ®Google Scholar
• Maas A, Hendriks RW. Role of Bruton’s tyrosine kinase in B cell development. Dev Immunol. 2001;8:171–181.
   PubMedGoogle Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94. DOI:10.1200/JCO.2012.42.7906
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–287. doi:10.1111/j.1600-065X.2008.00754.x.
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012;30:4161–4167. doi:10.1200/JCO.2012.42.5223.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406–3413. doi:10.1182/blood-2013-11-538546.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, De Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018. DOI:10.1056/NEJMoa1314583
   PubMed Web of Science ®Google Scholar
• Horwitz S, Flinn I, Patel M, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ, γ, in patients with relapsed/refractory lymphoma. Chicago, IL: American Society of Clinical Oncology; 2013.
   Google Scholar
• Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström’s macroglobulinemia. Clin Cancer Res. 2010;16:1033–1041. DOI:10.1158/1078-0432.CCR-09-1837
   PubMed Web of Science ®Google Scholar
• Guidetti A, Carlo-Stella C, Locatelli SL, et al. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. Clin Cancer Res. 2014; 20:5641–5651.
   PubMed Web of Science ®Google Scholar
• Oki Y, Fanale M, Romaguera J, et al. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015;171:463–470. doi:10.1111/bjh.13603.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347–5356. DOI:10.1200/JCO.2005.13.466
   PubMed Web of Science ®Google Scholar
• Smith SM, Besien K, Van Karrison T, et al. Temsirolimus has activity in non–mantle cell non-Hodgkin’s lymphoma subtypes: the University of Chicago phase II consortium. Jco. 2010;28:4740–4746. doi:10.1200/JCO.2010.29.2813.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25:341–347. doi:10.1038/leu.2010.226.
   PubMed Web of Science ®Google Scholar
• Rizzieri DE, Feldman E, DiPersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008;14:2756–2762. doi:10.1158/1078-0432.CCR-07-1372.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grünebach F, Patrone F, et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia. 2007;21:30–36. doi:10.1038/sj.leu.2404444.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520–525. doi:10.1093/annonc/mdn656.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:4293–4297. DOI:10.1200/JCO.2007.11.4207
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:667–675. DOI:10.1200/JCO.2005.03.108
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s macroglobulinemia. J Clin Oncol. 2009;27:120–126. doi:10.1200/JCO.2008.17.7865.
   PubMed Web of Science ®Google Scholar
• Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–953. doi:10.1056/NEJMoa1412096.
   PubMed Web of Science ®Google Scholar
• Evens AM, Hong F, Habermann TM, et al. Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): a randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). J Clin Oncol. 2016;34(suppl; abstr 7507).
   Google Scholar
• Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:690–697. doi:10.1200/JCO.2010.31.1142.
   PubMed Web of Science ®Google Scholar
• Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012;18;4830.
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111:3322–3330. doi:10.1182/blood-2007-09-078162.
   PubMed Web of Science ®Google Scholar
• Rai KR, Moore J, Wu J, et al. Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: five-year follow-up from a randomized phase III study [abstract]. J Clin Oncol. 2008;26:7008. DOI:10.1200/JCO.2007.15.2777
   Web of Science ®Google Scholar
• Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008;143:355–360. DOI:10.1111/j.1365-2141.2008.07353.x
   PubMed Web of Science ®Google Scholar
• Liang XS, Rogers AJ, Webber CL, et al. Developing gossypol derivatives with enhanced antitumor activity. Invest New Drugs. 1995;13:181–186. doi:10.1007/BF00873798.
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137–1141.
   PubMed Web of Science ®Google Scholar
• Davids MS, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol. 2014;32(15_suppl):8522. ASCO Meeting Abstr.
   Google Scholar
• O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166–173. doi:10.1200/JCO.2005.01.9679.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115. DOI:10.1200/JCO.2006.10.2434
   PubMed Web of Science ®Google Scholar
• Budde LE, Zhang MM, Shustov AR, et al. Phase I study of pulse high-dose vorinostat (v) plus rituximab (r), ifosphamide, carboplatin, and etoposide (ice) in patients with relapsed lymphoma. Br J Haematol. 2013;161:183–191. DOI:10.1111/bjh.12230.
   PubMed Web of Science ®Google Scholar
• Oki Y, Buglio D, Fanale M, et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013;19:6882–6890. DOI:10.1158/1078-0432.CCR-13-1906.
   PubMed Web of Science ®Google Scholar
• Tan D, Phipps C, Hwang WY, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015;2:e326–333.
   PubMed Web of Science ®Google Scholar
• Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7:759–768. DOI:10.1158/1535-7163.MCT-07-2026.
   PubMed Web of Science ®Google Scholar
• Crump M, Andreadis C, Assouline S, et al. Treatment of relapsed or refractory non-Hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. J Clin Oncol. 2008;26((15)suppl. Abstract 8528). DOI:10.1200/JCO.2007.15.2777.
   Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11. doi:10.1186/1756-8722-7-11.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:5404–5409. DOI:10.1200/JCO.2008.21.1169
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–1627. DOI:10.1093/annonc/mdq626
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344–349. doi:10.1111/j.1365-2141.2009.07626.x.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–1189. DOI:10.1200/JCO.2010.29.9024
   PubMed Web of Science ®Google Scholar
• Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–4206. doi:10.1200/JCO.2013.49.0219.
   PubMed Web of Science ®Google Scholar
• Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77. doi:10.1016/S1470-2045(13)70510-2.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10:267–276. doi:10.1038/nrclinonc.2013.46.
   PubMed Web of Science ®Google Scholar
• Katz BZ, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma. 2014;55:999–1006. doi:10.3109/10428194.2013.828354.
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410–1416. DOI:10.1182/blood-2015-06-651380.
   PubMed Web of Science ®Google Scholar